Calcium Channel Research Group
- Physiology, pharmacology and pharmacotherapeutic potential of L - type calcium channels
- Role of Cav1.4 and Cav2.1 channels in human calcium channel diseases (channelopathies)
- Funtional L - type calcium channel heterogeneity generated by alternative splicing
Staff
|
Ortner group
Striessnig group
|
Internal Collaborators: - CavX PhD Program "Calcium channels in excitable cells" - DP ARDRE (Doctoral Programme Ageing, Regeneration, and Drug Research) |
|
ALUMNI - Yuliia Nikonishyna
|
|
Research in this group involves three major topics:
1. Physiology, pharmacology and pharmacotherapeutic potential of L - type calcium channels
2. Role of Cav1.3, Cav1.4 and Cav2.1 channels in human calcium channel diseases (channelopathies)
3. Funtional L-type calcium channel heterogeneity generated by alternative splicing
Are you familiar with voltage - gated ion channels in general and voltage - gated calcium channels in particular? If not, get a brief introduction here.
Acknowledgements: We thank the following institutions for continuous funding: the Austrian Science Fund (FWF)(projects P14541, P14820, P17109, P17159, W11010/MCBO, P20670, SFB-F44010, SFB-F44020, P27809, DOC 30/CavX), the European Community (HPRN-CT-2000-00082, MRTN-CT-2006-035367, EC H2020 Marie Sklodowska-Curie research grant No 847681/ARDRE), and the Innsbruck Universities.
1. Physiology, pharmacology and pharmacotherapeutic potential of L - type calcium channels
We study the physiological role and the biophysical properties in particular of Cav1.2 and Cav1.3 L-type calcium channels. These are the main isoforms expressed in the brain as well as in heart and endocrine cells. They can be distinguished with respect to their biophysical properties and tissue expression profile. Interestingly, the biophysical properties of Cav1.3 allow it to serve pacemaker functions in brain and heart. The effects of alternative splicing on channel function, its modulation by neurotransmitters, enzymes and drugs and its expression in different tissues are studied. We successfully generated Cav1.3 knockout and knockin mutant mice to dissect the physiological roles of these channels. In addition, we are identifying proteins associated with channel complexes which may participate in calcium channel signal transduction and channel fine - tuning. Our approach involves a combination of electrophysiological, molecular biological, cell biological techniques and behavioral experiments.
Selected references
Platzer J, Engel J, Schrott-Fischer A, Stephan K, Bova S, Chen H, Zheng H, Striessnig J (2000) "Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type calcium channels"
Cell 102: 89-97
Kraus RL, Hering S, Grabner M, Ostler D, Striessnig J (1998) "Molecular mechanisms of diltiazem interaction with L-type calcium channels" J Biol Chem 273: 27205-27212
Striessnig J, Grabner M, Mitterdorfer J, Hering S, Sinnegger MJ, Glossmann H (1998) "Structural basis of drug binding to L-type calcium channels" Trends Pharmacol Sci 19: 108-115
Koschak A, Reimer D, Huber IG, Grabner M, Glossmann H, Engel J, Striessnig J (2001) "α1D (Cav1.3) subunits can form L - type calcium channels activating at negative voltages" J Biol Chem 276: 22100-22106
Koschak A, Reimer D, Walter D, Hoda JC, Heinzle T, Grabner M, Striessnig J (2003) "Cav1.4α1 subunits can form slowly inactivating dihydropyridine - sensitive L-type calcium channels lacking calcium - dependent inactivation" J Neurosci: 23: 6041-6049
Sinnegger - Brauns MJ, Hetzenauer A, Huber IG, Renstrom E, Wietzorrek G, Berjukov S, Cavalli M, Walter D, Koschak A, Waldschutz R, Hering S, Bova S, Rorsman P, Pongs O, Singewald N, Striessnig J (2004) "Isoform - specific regulation of mood behavior and pancreatic β cell and cardiovascular function by L - type Ca2+ channels" J Clin Invest 113: 1430-9
Busquet P, Hetzenauer A, Sinnegger - Brauns MJ, Striessnig J, Singewald N (2008) "Role of L - type Ca2+ channel isoforms in the extinction of conditioned fear" Learn Mem 15: 378-86
Striessnig J, Koschak A (2008) "Exploring the function and pharmacotherapeutic potential of voltage-gated calcium channels with gene knockout models" Channels (Austin) 2:233-51
Sinnegger - Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J (2008) "Expression and 1,4 - dihydropyridine-binding properties of brain L - type calcium channel isoforms" Mol Pharmacol 75: 407-414
Busquet P, Khoi Nguyen N, Schmid E, Tanimoto N, Seeliger MW, Ben - Yosef T, Mizuno F, Akopian A, Striessnig J, Singewald N "CaV1.3 L - type calcium channels modulate depression - like behaviour in mice independent of deaf phenotype" Int J Neuropsychopharmacol 13: 499-513
Marcantoni A, Vandael DH, Mahapatra S, Carabelli V, Sinnegger-Brauns MJ, Striessnig J, Carbone E (2010) "Loss of Cav1.3 channels reveals the critical role of L-type and BK channel coupling in pacemaking mouse adrenal chromaffin cells" J Neurosci 30:491-504
Schierberl K, Hao J, Tropea TF, Ra S, Giordano TP, Xu Q, Garraway SM, Hofmann F, Moosmang S, Striessnig J, Inturrisi CE, Rajadhyaksha AM (2011) "Cav1.2 L-type calcium channels mediate cocaine-Induced GluA1 trafficking in the nucleus accumbens, a long-term adaptation dependent on ventral tegmental area Cav1.3 channels" J Neurosci 31:13562-13575
Dragicevic E, Poetschke C, Duda J, Schlaudraff F, Lammel S, Schiemann J, Fauler M, Hetzel A, Watanabe M, Lujan R, Malenka RC, Striessnig J, Liss B (2014) "Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons" Brain, June 2014; doi: 10.1093/brain/awu131
Scharinger A, Eckrich S, Vandael DH, Schönig K, Koschak A, Hecker D, Kaur G, Lee A, Sah A, Bartsch D, Benedetti B, Lieb A, Schick B, Singewald N, Brauns MJ, Carbone E, Engel J, Striessnig J (2015) Cell-type-specific tuning of Cav1.3 Ca2+-channels by a C-terminal automodulatory domain. Front Cell Neurosci 9: 309. doi: 10.3389/fncel.2015.00309. eCollection
Striessnig J, Pinggera A, Kaur G, Bock G, Tuluc P (2014) "L-type calcium channels in heart and brain" WIREs Membr Transp Signal doi: 10.1002/wmts.102
Mesirca P, Bidaud I, Briec F, Evain S, Torrente AG, Le Quang K, Mangoni ME (2016). G protein-gated IKACh channels as therapeutic targets for treatment of sick sinus syndrome and heart block. Proc Natl Acad Sci (USA) 113, E932-941. doi.org/10.1073/pnas.1517181113
Stanika R, Campiglio M, Pinggera A, Lee A, Striessnig J, Flucher BE, Obermair GJ (2016). Splice variants of the Cav1.3 L-type calcium channel regulate dendritic spine morphology. Sci Rep, 6, 34528; doi.org/10.1038/srep34528
Toyoda F, Mesirca P, Dubel S, Ding W-G, Striessnig J, Mangoni ME, Matsuura H (2017) Cav1.3 L-Type Ca2+ Channel Contributes to the Heartbeat by Generating a Dihydropyridine-Sensitive Persistent Na+ Current. Sci Rep 7: 7869; doi.org/10.1038/s41598-017-08191-8
Review:
Zamponi GW, Striessnig J, Koschak A, Dolphin AC (2015) The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol. Rev. 67, 821–870. doi:10.1124/pr.114.009654
Mastrolia V, Flucher SM, Obermair GJ, Drach M, Hofer H, Renström E, Schwartz A, Striessnig J, Flucher BE, Tuluc P (2017). Loss of α2δ-1 Calcium Channel Subunit Function Increases the Susceptibility for Diabetes. Diabetes 66:897–907
Martínez-Rivera A, Hao J, Tropea TF, Giordano TP, Kosovsky M, Rice RC, Lee A, Huganir RL, Striessnig J, Addy NA, Han S, Rajadhyaksha AM (2017) Enhancing VTA Cav1.3 L-type Ca2+ channel activity promotes cocaine and mood-related behaviors via overlapping AMPA receptor mechanisms in the nucleus accumbens. Mol Psychiatry 22:1735-1745
Toyoda F, Mesirca P, Dubel S, Ding W-G, Striessnig J, Mangoni ME, Matsuura H (2017) Cav1.3 L-Type Ca2+ Channel Contributes to the Heartbeat by Generating a Dihydropyridine-Sensitive Persistent Na+ Current“. Sci Rep 7: 7869
Giang N, Mars M, Moreau M, Mejia JE, Bouchaud G, Magnan A, Michelet M, Ronsin B, G Murphy G, Striessnig J, Guéry JC, Pelletier L, Savignac M (2021). Separation of the Cav1.2-Cav1.3 calcium channel duo prevents type-2 allergic airway inflammation. Allergy Epub ahead of print, doi: 10.1111/all.14993
2. Role of Cav1.3, Cav1.4 and Cav2.1 channels in human calcium channel diseases (channelopathies)
In the past we have studied the functional consequences of disease-related mutations within the pore-forming subunits of Cav1.3, Cav1.4 or Cav2.1 subunits. Such mutations were found in patients with a rare form of migraine (Cav2.1, Familial Hemiplegic Migraine) or Congenital Stationary Night Blindness Type 2 (Cav1.4, CSNB2). From this work we gained a more complete understanding of the role of these calcium channels in neurons (Cav2.1, pathophysiology of migraine) or the retina (Cav1.4). Moreover, such human mutations revealed interesting insight into the structure-function relationship of calcium channels because most mutations cause changes in channel gating or channel surface expression. For example, a CSNB2 mutation in the C-terminal tail has recently led to the discovery of a novel C-terminal regulatory mechanism in Cav1.4, which also serves as a key regulator of Cav1.3 channel function. The methods involve a combination of electrophysiological, molecular biological and cell biological techniques.
Our current focus is on Cav1.3 channelopathies. We discovered a human channelopathy resulting from a loss-of-function mutation in the Cav1.3 (CACNA1D) gene (SANDD, Sinoatrial Node Dysfunction and Deafness) which led to important insight into the role of Cav1.3 for human physiology and provided unexpected insight into the gating machinery of these channels. We also described somatic CACNA1D gain of function mutations associated with enhanced aldosterone production in aldosterone-producing adenomas. More recently, we found that germline mutations inducing similar gating changes cause not only autism spectrum disorder with and without intellectual impairment (as described in the first two patients), but usually lead to a much more severe phenotype also including neurological abnormalities (e.g. muscle hypotonia, seizures, hyperactivity) and pronounced developmental delay.
Selected references
Kraus RL, Sinnegger MJ, Glossmann H, Hering S, Striessnig J (1998) "Familial hemiplegic migraine mutations change α1A calcium channel kinetics" J Biol Chem 273: 5586-5590
Kraus RL, Sinnegger MJ, Glossmann H, Hering S, Striessnig J (1998) "Three new familial hemiplegic migraine mutants affect P/Q - type calcium channel kinetics" J Biol Chem 273: 5586-5590
Wappl E, Koschak A, Poteser M, Sinnegger MJ, Walter D, Eberhart A, Groschner K, Glossmann H, Kraus RL, Grabner M, Striessnig (2002) "Functional consequences of P/Q - type calcium channel Cav2.1 missense mutations associated with episodic ataxia type 2 and progressive ataxia" J Biol Chem 277: 6960-6966
Pietrobon D, Striessnig J (2003) "Neurobiology of migraine" Nat Rev Neurosci 4: 386-398
Muellner C, Broos LA, van den Maagdenberg AM, Striessnig J (2004) "Familial hemiplegic migraine type 1 mutations K1336E, W1684R, and V1696I alter Cav2.1 calcium channel gating: evidence for β - subunit isoform - specific effects" J Biol Chem 279: 51844-51850
Singh A, Hamedinger D, Hoda JC, Gebhart M, Koschak A, Romanin C, Striessnig J (2006) "C - terminal modulator controls Ca2+ - dependent gating of Cav1.4 L - type calcium channels" Nat Neurosci 9: 1108-1116
Baig SM, Koschak A, Lieb A, Gebhart M, Dafinger C, Nurnberg G, Ali A, Ahmad I, Sinnegger-Brauns MJ, Brandt N, Engel J, Mangoni ME, Farooq M, Khan HU, Nurnberg P, Striessnig J, Bolz HJ (2011) "Loss of Cav1.3 (CACNA1D) function in a human channelopathy with bradycardia and congenital deafness" Nat Neurosci 14:77-84
Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochuko-va EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers T, Tops B, Kusters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ (2013) "Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension." Nat Genet 45: 1055-1060
Pinggera A, Lieb A, Benedetti B, lampert M, Monteleone S, Liedl KR, Tuluc P, Striessnig J (2015) CACNA1D de novo mutations in autism spectrum disorders activate Cav1.3 L-type Ca2+ channels. Biol Psychiatry 77: 816-822
Pinggera A, Mackenroth L, Rump A, Schallner J, Beleggia F, Wollnik B, Striessnig J (2017) New Gain-of-Function Mutation Shows CACNA1D as Recurrently Mutated Gene in Autism Spectrum Disorders and Epilepsy. Hum Mol Genet 26: 2923 - 2932;
Tan GC, Negro G, Pinggera A, Tizen Laim NMS, Rose IM, Ceral J, Ryska A, Chin LK, Kamaruddin NA, Mohd Mokhtar N, A Jamal AR, Sukor N, Solar M, Striessnig J, Brown MJ, Azizan EA (2017) Aldosterone-Producing Adenomas: Histopathology-Genotype Correlation and Identification of a Novel CACNA1D Mutation. Hypertension 70(1):129-136
Pinggera A, Negro G, Tuluc P, Brown MJ, Lieb A, Striessnig J (2018) Gating defects of disease-causing de novo mutations in Cav1.3 Calcium channels. Channels (Austin) 12:388-402
Hofer NT, Tuluc P, Ortner NJ, Nikonishyna YV, Fernándes-Quintero ML, Liedl KR, Flucher BE, Cox H, Striessnig J. (2020) Biophysical classification of a CACNA1D de novo mutation as a high-risk mutation for a severe neurodevelopmental disorder. Mol Autism 11:4
Hofer NT, Pinggera A, Nikonishyna YV, Tuluc P, Fritz EM, Obermair GJ, Striessnig J (2021) Stabilization of negative activation voltages of Cav1.3 L-Type Ca2+-channels by alternative splicing. Channels (Austin) 15:38-52
Reviews:
Zamponi GW, Striessnig J, Koschak A, Dolphin AC (2015) The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol. Rev. 67, 821–870. doi:10.1124/pr.114.009654
Pinggera, A., and Striessnig, J. (2016). Cav 1.3 (CACNA1D) L-type Ca2+ channel dysfunction in CNS disorders. J Physiol 594: 5839-5849. doi: 10.1113/JP27067
Ortner NJ, Kaserer T, Copeland JN, Striessnig J (2020) De novo CACNA1D Ca2+ channelopathies: clinical phenotypes and molecular mechanism. Pflugers Arch 472:755-773
Striessnig J (2021) Voltage-Gated Ca2+-Channel α1-Subunit de novo Missense Mutations: Gain or Loss of Function - Implications for Potential Therapies. Front Synaptic Neurosci 13:634760
3. Functional L-type calcium channel heterogeneity generated by alternative splicing
We recently discovered a novel C - terminal regulatory mechanism in Cav1.3 and Cav1.4 channels. Interestingly, this mechanism is absent in a naturally occuring Cav1.3 splice variants generating a channel with faster inactivation and a more negative activation range. This project addresses the important question about the physiological significance of this splice variant and tries to identify other C - terminal splice variants with different gating behavior. We generated a knockin mouse model in which this regulation is prevented. This allows us to study the physiological significance of this regulation. We could already show that this mechanism affects gating in cochelar inner hair cells and in chromaffin cells, albeit in different ways. While its disruption does not affect hearing and Ca2+ influx into individual active zones in cochelar inner hair cells, the electrical activity of chromaffin cells (and therefore likely also of neurons) is strongly affected. The methods involve a combination of electrophysiological, molecular biological, gene-targeting and cell biological techniques.
Notably, as first shown by Tuck Soong's group, this C-terminal alternative splicing also affects the sensitivity of the channel for calcium channel blockers. This could be relevant when considering treatment of CNS disorders with existing dihydropyridine calcium channel blockers. We could demonstrate that in Substantia nigra dopamine neurons alternative splicing may render a subpopulation of Cav1.3 channels (which are currently considered a target for neuroprotection by isradipine) rather dihydropyridine-insensitive as compared to Cav1.2 and other splice variants of Cav1.3.
Selected references
Singh A, Hamedinger D, Hoda JC, Gebhart M, Koschak A, Romanin C, Striessnig J (2006) "C - terminal modulator controls Ca2+ - dependent gating of Cav1.4 L - type Ca2+ channels" Nat Neurosci 9: 1108-1116
Sinnegger - Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J (2008) "Expression and 1,4 - dihydropyridine - binding properties of brain L - type calcium channel isoforms" Mol Pharmacol 75: 407-14
Singh A, Gebhart M, Fritsch R, Sinnegger - Brauns MJ, Poggiani C, Hoda JC, Engel J, Romanin C, Striessnig J, Koschak A (2008) "Modulation of voltage- and calcium - dependent gating of Cav1.3 L - type calcium channels by alternative splicing of a C - terminal regulatory domain" J Biol Chem 283: 20733-44
Striessnig J (2007) "C - terminal tailoring of L - type calcium channel function" J Physiol 585: 643-4
Bock G, Gebhart M, Scharinger A, Jangsangthong W, Busquet P, Poggiani C, Sartori S, Mangoni ME, Sinnegger-Brauns MJ, Herzig S, Striessnig J, Koschak A (2011) "Functional properties of a newly identified C-terminal splice variant of Cav1.3 L-type calcium channels" J Biol Chem 286:42736-48.
Lieb A, Ortner N, Striessnig J (2014) "C-terminal modulatory domain controls coupling of voltage-sensing to pore opening in Cav1.3 L-type calcium channels." Biophysical J 106: 1467-1475
Ortner NJ, Bock G, Dougalis A, Kharitonova M, Duda J, Hess S, Tuluc T, Pomberger T, Stefanova N, Pitterl F, Ciossek T, Oberacher H, Draheim HJ, Kloppenburg P, Liss B, Striessnig J (2017) Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-like Activity: Implications for Neuroprotection in Parkinson’s Disease. J Neurosci 37: 6761-6777
Scharinger A, Eckrich S, Vandael DH, Schönig K, Koschak A, Hecker D, Kaur G, Lee A, Sah A, Bartsch D, Benedetti B, Lieb A, Schick B, Singewald N, Brauns MJ, Carbone E, Engel J, Striessnig J (2015) Cell-type-specific tuning of Cav1.3 Ca2+-channels by a C-terminal automodulatory domain. Front Cell Neurosci 9: 309
Ohn TL, Rutherford MA, Jing Z, Jung S, Duque-Afonso CJ, Hoch G, Picher MM, Scharinger A, Strenzke N, Moser T (2016) Hair cells use active zones with different voltage dependence of Ca2+ influx to decompose sounds into complementary neural codes. Proc Natl Acad Sci U S A 113: E4716-25
| nach oben |